SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories inches up on launching Avigan in India

19 Aug 2020 Evaluate

Dr. Reddy’s Laboratories is currently trading at Rs. 4505.15, up by 0.90 points or 0.02% from its previous closing of Rs. 4504.25 on the BSE.

The scrip opened at Rs. 4559.00 and has touched a high and low of Rs. 4559.00 and Rs. 4494.40 respectively. So far 47881 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4754.30 on 10-Aug-2020 and a 52 week low of Rs. 2490.30 on 21-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4590.30 and Rs. 4438.20 respectively. The current market cap of the company is Rs. 74857.97 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.

Dr. Reddy's Laboratories has launched Avigan (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute Avigan (Favipiravir) 200 mg Tablets in India.

Avigan (Favipiravir) has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease. Dr. Reddy’s Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1293.25 -13.55 (-1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×